FK506 prevents induction of rat experimental autoimmune myasthenia gravis

Journal of Autoimmunity

Volumn 10, Issue 1, 1997, Pages 11-16

  Yoshikawa, Hiroaki ^a   Iwasa, Kazuo ^a   Satoh, Katsuaki ^a   Takamori, Masaharu ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

experimental autoimmune myasthenia gravis; FK506; myasthenia gravis

Indexed keywords

SYNTHETIC PEPTIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG THERAPY; ETIOLOGY; FEMALE; HELPER CELL; IMMUNIZATION; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; NONHUMAN; PREVENTION; PRIORITY JOURNAL; RAT; T LYMPHOCYTE SUBPOPULATION;

EID: 0031081658     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0111     Document Type: Article

References (31)

1. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 26:1976;1054-1059.
2. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann. N.Y. Acad. Sci. 274:1976;283-299.
3. Engel A.G., Lindstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology. 27:1977;307-315.
4. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 298:1978;1116-1122.
5. Lennon V.A., Griesmann G.E. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology. 39:1989;1069-1076.
6. Rudensky A.Yu., Preston-Hurlburt P., Hong S.C., Barlow A., Janeway C.A. Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature. 353:1991;622-627.
7. Newsom-Davis J., Wilcox N., Calder L. Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes. N. Engl. J. Med. 305:1981;1313-1318.
8. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation and physico-chemical and biological characteristics. J. Antibiot. (Tokyo). 40:1987;1249-1255.
9. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H., Ochiai T. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J. Antibiot. (Tokyo). 40:1987;1256-1265.
10. Noda M., Furutani Y., Takahashi H., Toyosato M., Tanabe T., Shimizu S., Kikyotani S., Kayano T., Hirose T., Inayama S., Numa S. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of muscle acetylcholine receptor. Nature. 305:1983;818-823.
11. Witzemann V., Stein E., Barg B., Konno T., Koenen M., Kues W., Criado M., Hofmann M., Sakmann B. Primary structure and functional expression of the α-, β-, γ-, δ- and ε-subunits of the acetylcholine receptor from rat muscle. Eur. J. Biochem. 194:1990;437-448.
12. Todo S., Podesta L., ChapChap P., Kahn D., Pan C.E., Ueda Y., Okuda K., Imventarza O., Casavilla A., Demetris A.J., Makowka L., Starzl T.E. Orthotopic liver transplantation in dogs receiving FK-506. Transplant. Proc. 19:1987;64-67.
13. Inamura N., Hashimoto M., Nakahara K., Aoki H., Yamaguchi I., Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin. Immunol. Immunopathol. 46:1988;82-90.
14. Kawashima H., Fujino Y., Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest. Ophthalmol. Vis. Sci. 29:1988;1265-1271.
15. Takamori M., Yoshikawa H. Effect of calcitonin gene-related peptide on skeletal muscle via specific binding site and G protein. J. Neurol. Sci. 90:1989;99-109.
16. McCormick D.J., Griesmann G.E., Huang Z.X., Lambert E.H., Lennon V.A. Myasthenogenicity of human acetylcholine receptor synthetic α-subunit peptide 125-147 does not require intramolecular disulfide cyclization. J. Immunol. 139:1987;2615-2619.
17. Lennon V.A., Griesmann G.A., McCormick D.J., Huang Z.-X., Feng H., Lambert E.H. Definition of myasthenogenic sites of the human acetylcholine receptor using synthetic peptides. Ann. N.Y. Acad. Sci. 505:1987;439-450.
18. Matsuo H., Tsujihata M., Satoh A., Takeo G., Yoshimura T., Nagataki S. Myasthenogenicity of a human acetylcholine receptor α-subunit peptide: morphology and immunology. Muscle Nerve. 15:1992;282-287.
19. Fujii Y., Lindstrom J. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides. J. Immunol. 140:1988;1830-1837.
20. Vincent A., Jacobson L., Shillito P. Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol. Lett. 39:1994;269-275.
21. Brillantes A.B., Ondrias K., Scott A., Kobrinsky E., Ondriasova E., Moschella M.C., Jayaraman T., Landers M., Ehrlich B.E., Marks A.R. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 77:1994;513-523.
22. Lam E., Martin M.M., Timerman A.P., Sabers C., Fleischer S., Lukas T., Abraham R.T., O'Keefe S.J., O'Neill S.J., Wiederrecht G.J. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J. Biol. Chem. 270:1995;26511-26522.
23. Mokhtarian F., Pino M., Ofosu-Appiah W., Grob D. Phenotypic and functional characterization of T cells from patients with myasthenia gravis. J. Clin. Invest. 86:1990;2099-2108.
24. Venkataramanan R., Swaminathan A., Prasad T., Jain A., Zuckerman S., Warty V., McMichael J., Lever J., Buckart G., Starzl T. Clinical pharmacokinetics of tactolimus. Clin. Pharmacokinet. 29:1966;404-430.
25. Harding M.W., Galat A., Uehling D.E., Schreiber S.L. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 341:1989;758-760.
26. Liu J., Farmer J.D. Jr., Lane W.S., Freidman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 23:1991;807-815.
27. Flanagan W.M., Corthesy B., Bram R.J., Crabtree G.R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 352:1991;803-807.
28. Tocci M.J., Matkovich D.A., Collier K.A., Kwok P., Dumont F., Lin S., Degudicibus S., Siekierka J.J., Chin J., Hutchinson N.I. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 143:1989;718-726.
29. Ochiai T., Nakajima K., Nagata M., Hori S., Asano T., Isono K. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 44:1987;734-738.
30. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for imunosuppression in liver transplantation. N. Engl. J. Med. 331:1994;1110-1115.
31. Michel G., Kemény L., Homey B., Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol. Today. 17:1996;106-108.